pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
October 18 2017 - 7:00AM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
of sustained release drug delivery products primarily for treating
eye diseases, will report results for its first quarter of fiscal
year 2018 on Tuesday, November 7, 2017. Management will host
a conference call to review the results at 8:30 a.m. ET on the same
day.
The conference call may be accessed by dialing
(877) 312-7507 from the U.S. and Canada, or (631) 813-4828 from
international locations. The conference ID is 99811898. A live
webcast will be available on the Investor Relations section of the
corporate website at http://www.psivida.com.
A replay of the call will be available beginning
November 7, 2017, at approximately 11:30 a.m. ET and ending on
November 14, 2017, at 11:59 p.m. ET. The replay may be accessed by
dialing (855) 859-2056 within the U.S. and Canada or (404) 537-3406
from international locations, Conference ID Number: 99811898. A
replay of the webcast will also be available on the corporate
website during that time.
About pSivida Corp.
pSivida Corp. (www.psivida.com),
headquartered in Watertown, MA, is a leader in the development
of sustained release drug products for treating eye diseases.
pSivida has developed three of only four FDA-approved
sustained-release treatments for back-of-the-eye diseases. The most
recent, ILUVIEN®, a micro-insert for diabetic macular edema,
licensed to Alimera Sciences, is currently sold directly in
the U.S. and three EU countries. Retisert ®, an
implant for posterior uveitis, is licensed to and sold
by Bausch & Lomb. pSivida's lead product candidate,
Durasert™ micro-insert for posterior segment uveitis, is being
independently developed. Two pivotal Phase 3 studies with Durasert
achieved their primary efficacy endpoint of prevention of
recurrence of uveitis at six months of follow-up with statistical
significance, and the Company plans to file an NDA by late December
2017/early January 2018. pSivida's pre-clinical development
program is focused on using its core platform technology Durasert™
to deliver drugs to treat wet age-related macular degeneration,
glaucoma, osteoarthritis and other diseases. To learn more about
pSivida, please visit www.psivida.com and connect on
Twitter, LinkedIn, Facebook and Google+.
Contact:
EVC Group
Michael Polyviou/Doug Sherk –
Investorsmpolyviou@evcgroup.com; dsherk@evcgroup.com212.850.6020;
646-445-4800
Thomas Gibson –
Mediatom@tomgibsoncommunications.com201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024